KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Finished Goods (2018 - 2025)

Historic Finished Goods for Rigel Pharmaceuticals (RIGL) over the last 8 years, with Q3 2025 value amounting to $1.8 million.

  • Rigel Pharmaceuticals' Finished Goods fell 6936.54% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 6936.54%. This contributed to the annual value of $5.0 million for FY2024, which is 23249.34% up from last year.
  • Rigel Pharmaceuticals' Finished Goods amounted to $1.8 million in Q3 2025, which was down 6936.54% from $2.7 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Finished Goods high stood at $5.8 million for Q3 2024, and its period low was $962000.0 during Q1 2021.
  • Its 5-year average for Finished Goods is $2.3 million, with a median of $1.6 million in 2023.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Finished Goods skyrocketed by 23249.34% in 2024 and then crashed by 6936.54% in 2025.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' Finished Goods stood at $1.3 million in 2021, then surged by 45.12% to $1.9 million in 2022, then decreased by 20.8% to $1.5 million in 2023, then skyrocketed by 232.49% to $5.0 million in 2024, then tumbled by 64.38% to $1.8 million in 2025.
  • Its Finished Goods stands at $1.8 million for Q3 2025, versus $2.7 million for Q2 2025 and $3.8 million for Q1 2025.